AstraZeneca urges Hong Kong to adopt new funding model to attract biotech investment

AstraZeneca calls for a new healthcare financing model in Hong Kong to attract global biotech investment, citing its own HK$200M investment and 60 clinical trials over three years. The statement signals a potential shift in regional investment strategy amid growing pharma interest in mainland China. The proposal's impact depends on policy adoption and market response.